IGF-1, IGFBP-1 and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: Findings from the breast and prostate cancer cohort consortium (BPC3)

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Patel, Alpa V ^a   Cheng, Iona ^b   Canzian, Ferderico ^c   Le Marchand, Loïc ^d   Thun, Michael J ^a   Berg, Christine D ^e   Buring, Julie ^f   Calle, Eugenia E ^a   Chanock, Stephan ^e   Clavel Chapelon, Francoise ^g   Cox, David G ^h   Dorronsoro, Miren ⁱ   Dossus, Laure ^c   Halman, Christopher A ^j   Hankinson, Susan E ^f   Henderson, Brian E ^j   Hoover, Robert ^e   Hunter, David J ^h   Kaaks, Rudolf ^c   Kolonel, Laurence N ^d   Kraft, Peter ^h   Linseisen, Jakob ^c   Lund, Elliv ^k   Manjer, Jonas ^l   McCarty, Catherine ^m   Peeters, Petra H M ^n,p   Pike, Malcolm C ^j   Pollak, Michael ^o   Riboli, Elio ^p   Stram, Daniel O ^j   Tjonneland, Anne ^q   Travis, Ruth C ^r   Trichopoulos, Dimitrios ^h   Tumino, Rosario ^s   Yeager, Meredith ^e   Ziegler, Regina G ^e   Spencer Feigelson, Heather ^a   more..

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ Department of Public Health of Guipuzcoa ^*  (Spain)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF TROMSØ   (Norway)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m MARSHFIELD CLINIC   (United States)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o MCGILL UNIVERSITY   (Canada)

^p IMPERIAL COLLEGE LONDON   (United Kingdom)

^q INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s CIVILE M P AREZZO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; CANCER RISK; CAUCASIAN; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HORMONAL THERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; PREDICTION; PROSTATE CANCER; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BREAST TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MALE; METABOLISM; PROSTATE TUMOR; RISK FACTOR;

ANIMALIA;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 49749123796     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002578     Document Type: Article

References (31)

1. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocrine Related Cancer 8: 197-209.
2. Wood TL, Yee D (2000) IGFs and IGFBPs in the normal mammary gland and in breast cancer. Journal of Mammary Gland Biology and Neoplasia 3: 1-5.
3. Baxter RC (1994) Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Research 42: 140-144.
4. Burger AM, Leyland-jones B, Banerjee K, Spyropoulos DD, Seth AK (2005). Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. European Journal of Cancer 41: 1515-1527.
5. Hadsell DL, Bonnette SG (2000) IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. Journal of Mammary Gland Biology and Neoplasia 5: 19-30.
6. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JMP, et al. (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiology, Biomarkers, & Prevention 14: 2-19.
7. Allen NE, Roddam AW, Allen DS, Fentiman IS, dosSantosSilva I, et al. (2005) A prospective study of serum insulin-like growth factor-1 (IGF-1), IGF-11, IGF-binding protein-3 and breast cancer risk. British Journal of Cancer 92: 1283-1287.
8. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, et al. (2006) Polymorphisms or genes coding for insulin-likw growth factor I and its major binding proteins, circulating levels of IGF-1 and IGFBP-3 and breast cancer risk: results from the EPIC study. British Journal of Cancer 94: 299-307.
9. Cheng I, Penney KL, Stram DO, LeMarchand L, Giorgi E, et al. (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The Multiethnic Cohort. Cancer Epidemiology, Biomarkers, & Prevention 15: 1993-1997.
10. Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M,I et al. (2007) Implications for prostate cancer of insulin-like growth factor-I (IGF-1) genetic variation and circulating IGF-1 levels. J Clin Endocrinol Metab 92: 4820-4826.
11. Setiawan VW, Cheng I, Stram DO, Penney KL, LeMarchand L, et al. (2006) IGF-1 genetic variation and breast cancer: the Multiethnic Cohort. Cancer Epidemiology, Biomarkers, & Prevention 15: 172-174.
12. Verheus M, McKay JD, Kaaks P, Canzian F, Biessy C, et al. (2007) Common genetic variation in the IGF-1, serum IGF-1 levels and breast density. Breast Cancer Res Treat (epub ahead of print.
13. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, et al. (2005) A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nature Reviews Cancer 5: 977-985.
14. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, et al. (2002) The American Cancer Society Cancer Prevention Study. II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94: 500-511.
15. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norai T, et al. (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5: 1113-1124.
16. Coldizt GA, Hankinson SE (2005) The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5: 388-396.
17. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE (2000) Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9: 19-27.
18. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, et al. (2000) A multiethnic cohort in Hawaii andv Los Angeles: baseline characteristics. Am J Fpidemiol 151: 346-357.
19. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, et al. (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21: 319S-355S.
20. Cheng I, Stram DO, Penney KL, Pike M, LeMarchand L, et al. (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic, Cohort. Journal of the National Cancer Institute 98: 123-134.
21. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
22. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, et al. (2003) Choosing haplotype-tagging SNPS based on unphased genoty c data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55: 27-36.
23. Packer PB, Yeager M, Staats B, Welch R, Crenshaw A, et al. (2004) SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Research 32: D528-532.
24. DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, et al. (2003) IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. BrJ Cancer 88: 277-282.
25. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, et al. (2006) IGF-1, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593-605.
26. Schernhammer ES. Holly JM, Pollak MN, Minkinson SE (2005) Circulating level of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 699-704.
27. Zaykin D, Westfall P, Young S, Karnoub M, Wagner M, et al. (2002) Testing association or statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Human Heredity 53: 79-91.
28. Feigelson HS, Cox DG, Cann RM, Wacholder S, Kaaks R, et al. (2006) Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohorts. Cancer Research 66: 2468-2475.
29. Schernhammer ES, Hankinson A, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer 107: 60-64.
30. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, et al. (2007) Genetic variation in IGF1, IGFBP3, IRS 1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Research and Treatment 104: 197-209.
31. Wagner K, Hemminki K, Israelsson, Grzybowska E, Soderberg M, et al. (2005) Polymorphisms in the IGF-1 and IGFBP-3 promoter and the risk of breast cancer. Breast Cancer Research and Treatment 92: 133-140.